Recent Updates
Recently added Catalysts
CTNM Negative Sentiment

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder

Monday, September 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Contineum Therapeutics announced that its MOONLIGHT-1 trial for JNJ-5120/PIPE-307 did not meet its primary efficacy endpoint. The trial aimed to assess improvements in depression symptoms using the MADRS scale. Results indicated no significant difference from placebo at Day 5, raising concerns about the treatment's effectiveness for major depressive disorder.

Market Sentiment Analysis

CONCERNS & RISKS

  • The MOONLIGHT-1 trial did not achieve its primary efficacy endpoint.
  • No improvement was observed in the MADRS total score at Day 5 compared to placebo.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+63%
120-day peak, hindsight
Typical move
2.8%
average across 4 past catalysts
Cash runway
~60 mo
Minimal dilution risk
Lead asset
PIPE-791
Phase 2 · Idiopathic Pulmonary Fibrosis

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The trial evaluated improvement from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5 compared with placebo.

Frequently Asked Questions

What was the outcome of the MOONLIGHT-1 trial?

The MOONLIGHT-1 trial did not achieve its primary efficacy endpoint.

What scale was used to measure depression improvement?

The Montgomery-Åsberg Depression Rating Scale (MADRS) was used.

When were the results of the trial evaluated?

Results were evaluated at Day 5 of the trial.

How did JNJ-5120 perform compared to placebo?

There was no significant improvement compared to placebo.

ShareAdd on Google
Tags: CTNM Viatris Investor Conferences Healthcare Contineum Therapeutics JNJ-5120 PIPE-307 major depressive disorder MOONLIGHT-1 trial
Last updated: Sep 14, 2026

Biotech snapshot

Cash runway
$237M liquidity · $4M/mo burn
~60 mo
Minimal dilution risk
Lead asset
PIPE-791Phase 2
Idiopathic Pulmonary Fibrosis →

Catalyst track record

+63%
best trade around CTNM's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for CTNM.

See every catalyst's timing & PoA →